Logo image of RPID

RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RPID - US75340L1044 - Common Stock

2.98 USD
-0.12 (-3.87%)
Last: 12/26/2025, 8:14:27 PM
Fundamental Rating

2

Overall RPID gets a fundamental rating of 2 out of 10. We evaluated RPID against 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of RPID have multiple concerns. RPID is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RPID has reported negative net income.
RPID had a negative operating cash flow in the past year.
In the past 5 years RPID always reported negative net income.
RPID had a negative operating cash flow in each of the past 5 years.
RPID Yearly Net Income VS EBIT VS OCF VS FCFRPID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of RPID (-52.47%) is worse than 85.96% of its industry peers.
RPID has a worse Return On Equity (-99.91%) than 78.95% of its industry peers.
Industry RankSector Rank
ROA -52.47%
ROE -99.91%
ROIC N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
RPID Yearly ROA, ROE, ROICRPID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

Looking at the Gross Margin, with a value of 7.72%, RPID is doing worse than 89.47% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for RPID so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPID Yearly Profit, Operating, Gross MarginsRPID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

3

2. Health

2.1 Basic Checks

RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
RPID has more shares outstanding than it did 1 year ago.
RPID has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RPID has a worse debt to assets ratio.
RPID Yearly Shares OutstandingRPID Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPID Yearly Total Debt VS Total AssetsRPID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -7.13, we must say that RPID is in the distress zone and has some risk of bankruptcy.
RPID has a worse Altman-Z score (-7.13) than 89.47% of its industry peers.
A Debt/Equity ratio of 0.43 indicates that RPID is not too dependend on debt financing.
RPID has a Debt to Equity ratio of 0.43. This is in the lower half of the industry: RPID underperforms 61.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -7.13
ROIC/WACCN/A
WACC10.82%
RPID Yearly LT Debt VS Equity VS FCFRPID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 4.23 indicates that RPID has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.23, RPID is doing good in the industry, outperforming 68.42% of the companies in the same industry.
A Quick Ratio of 2.95 indicates that RPID has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.95, RPID is in line with its industry, outperforming 59.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.23
Quick Ratio 2.95
RPID Yearly Current Assets VS Current LiabilitesRPID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

RPID shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.82%, which is quite good.
Looking at the last year, RPID shows a quite strong growth in Revenue. The Revenue has grown by 16.63% in the last year.
RPID shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.18% yearly.
EPS 1Y (TTM)9.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)16.63%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%3.08%

3.2 Future

Based on estimates for the next years, RPID will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.25% on average per year.
RPID is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.98% yearly.
EPS Next Y6.03%
EPS Next 2Y9.09%
EPS Next 3Y10.48%
EPS Next 5Y9.25%
Revenue Next Year18.65%
Revenue Next 2Y20.05%
Revenue Next 3Y22.69%
Revenue Next 5Y21.98%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPID Yearly Revenue VS EstimatesRPID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
RPID Yearly EPS VS EstimatesRPID Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RPID reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RPID is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPID Price Earnings VS Forward Price EarningsRPID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPID Per share dataRPID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.09%
EPS Next 3Y10.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RPID!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

RAPID MICRO BIOSYSTEMS INC-A

NASDAQ:RPID (12/26/2025, 8:14:27 PM)

2.98

-0.12 (-3.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07 2025-11-07/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners57.19%
Inst Owner Change-26.17%
Ins Owners4%
Ins Owner Change1.27%
Market Cap132.07M
Revenue(TTM)30.52M
Net Income(TTM)-44.29M
Analysts84
Price Target8.16 (173.83%)
Short Float %0.68%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.27%
Min EPS beat(2)-4.49%
Max EPS beat(2)-4.04%
EPS beat(4)2
Avg EPS beat(4)0.82%
Min EPS beat(4)-4.49%
Max EPS beat(4)6.22%
EPS beat(8)4
Avg EPS beat(8)1.35%
EPS beat(12)7
Avg EPS beat(12)2.26%
EPS beat(16)8
Avg EPS beat(16)0.3%
Revenue beat(2)1
Avg Revenue beat(2)0.19%
Min Revenue beat(2)-0.85%
Max Revenue beat(2)1.23%
Revenue beat(4)3
Avg Revenue beat(4)2.67%
Min Revenue beat(4)-0.85%
Max Revenue beat(4)7.03%
Revenue beat(8)7
Avg Revenue beat(8)4.21%
Revenue beat(12)10
Avg Revenue beat(12)6.25%
Revenue beat(16)11
Avg Revenue beat(16)2.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.45%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-1.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)13.99%
Revenue NY rev (1m)2.34%
Revenue NY rev (3m)2.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.33
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.69
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.47%
ROE -99.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.72%
FCFM N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.7%
Cap/Sales 2.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.23
Quick Ratio 2.95
Altman-Z -7.13
F-Score3
WACC10.82%
ROIC/WACCN/A
Cap/Depr(3y)112.45%
Cap/Depr(5y)118.7%
Cap/Sales(3y)17.47%
Cap/Sales(5y)14.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y6.03%
EPS Next 2Y9.09%
EPS Next 3Y10.48%
EPS Next 5Y9.25%
Revenue 1Y (TTM)16.63%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%3.08%
Revenue Next Year18.65%
Revenue Next 2Y20.05%
Revenue Next 3Y22.69%
Revenue Next 5Y21.98%
EBIT growth 1Y12.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.14%
OCF growth 3YN/A
OCF growth 5YN/A

RAPID MICRO BIOSYSTEMS INC-A / RPID FAQ

Can you provide the ChartMill fundamental rating for RAPID MICRO BIOSYSTEMS INC-A?

ChartMill assigns a fundamental rating of 2 / 10 to RPID.


What is the valuation status of RAPID MICRO BIOSYSTEMS INC-A (RPID) stock?

ChartMill assigns a valuation rating of 0 / 10 to RAPID MICRO BIOSYSTEMS INC-A (RPID). This can be considered as Overvalued.


What is the profitability of RPID stock?

RAPID MICRO BIOSYSTEMS INC-A (RPID) has a profitability rating of 0 / 10.


How financially healthy is RAPID MICRO BIOSYSTEMS INC-A?

The financial health rating of RAPID MICRO BIOSYSTEMS INC-A (RPID) is 3 / 10.